Related Experiment Video
Updated: Aug 8, 2026
09:43
An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018
Adult Burkitt's lymphoma
1Department of Oncology and Hematology, University of Nebraska Medical Center, Omaha 68198-3330, USA. rgbociek@unmc.edu
Clinical Lymphoma
|July 2, 2005
Summary
Burkitt's lymphoma, a fast-growing cancer, is treatable with chemotherapy. Advances in HIV care have improved outcomes for patients with HIV-associated Burkitt's lymphoma.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Burkitt's lymphoma is a mature B-cell lymphoma.
- It is characterized by rapid proliferation and extranodal involvement.
- Cytogenetic translocations involving the c-MYC oncogene are implicated in its pathogenesis.
Purpose of the Study:
- To review the epidemiologic, biologic, diagnostic, and therapeutic aspects of adult Burkitt's lymphoma.
- To discuss current treatment strategies and outcomes.
- To explore the impact of HIV on Burkitt's lymphoma prognosis.
Main Methods:
- Review of existing literature, including limited randomized trials.
- Analysis of epidemiological data.
- Discussion of diagnostic criteria and therapeutic regimens.
Main Results:
- Burkitt's lymphoma is curable with aggressive multiagent chemotherapy.
- Autologous stem cell transplantation may benefit relapsed patients.
- Improved prognosis for HIV-associated Burkitt's lymphoma due to better antiretroviral therapy and chemotherapy.
Conclusions:
- Burkitt's lymphoma requires aggressive treatment for optimal outcomes.
- Stem cell transplantation plays a role in relapsed disease, with its role in allogeneic transplantation remaining uncertain.
- Advances in HIV management have positively impacted the prognosis of HIV-associated Burkitt's lymphoma.
